secwatch.observer — SEC 8-K summary
======================================

Issuer:     Niagen Bioscience, Inc. (NAGE)
CIK:        0001386570
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001628280-22-014063
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ChromaDex Q1 net sales $17.3M (+18% YoY); net loss $7.7M; adj EBITDA loss narrows
--------------------------------------------------------------------------------

- Net sales $17.3M (+18% YoY); Tru Niagen sales $14.9M (+20% from Q1 2021).
- Gross margin 61.0% (down from 62.9%); net loss $7.7M ($0.11 per share) vs $7.4M ($0.12) last year.
- Adjusted EBITDA loss (incl legal) $4.5M, a $1.2M improvement from Q1 2021.
- Launched Tru Niagen Immune in April 2022; new TV campaign with encouraging early results.
- Granted U.S. continuation patent covering NR chloride, malate, and tartrate salts through 2037.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022014063/0001628280-22-014063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1386570/000162828022014063/cdxc-20220512.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-014063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer